Eupraxia Pharmaceuticals (EPRX) Income from Continuing Operations (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Income from Continuing Operations of 12627036.0 for Q1 2026, down 86.74% year-over-year from 95254318.31 in Q1 2025, and up 24.43% quarter-over-quarter from 16709997.0 in Q4 2025.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Income from Continuing Operations for 4 consecutive years, with 12627036.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 86.74% year-over-year to 12627036.0; the TTM figure through Mar 2026 stood at 44443535.0 (down 68.15% YoY), while the FY2025 annual figure was 38605652.0, down 49.96% from the prior year.
- Income from Continuing Operations improved to 12627036.0 in Q1 2026 per EPRX's latest filing, from 16709997.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3956088.0 in Q1 2023 and bottomed at 16709997.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 8314455.67 across 4 years, with a median of 6761687.0 in 2025.
- On a YoY basis, Income from Continuing Operations climbed as much as 6.32% in 2025 and fell as far as 121.9% in 2025.
- Eupraxia Pharmaceuticals' Income from Continuing Operations stood at 3956088.0 in 2023, then slumped by 90.35% to 7530538.0 in 2024, then slumped by 121.9% to 16709997.0 in 2025, then increased by 24.43% to 12627036.0 in 2026.
- Business Quant data shows EPRX's Income from Continuing Operations at 12627036.0 in Q1 2026, 16709997.0 in Q4 2025, and 6369981.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Eupraxia Pharmaceuticals | 304.67 Mn | 304.67 Mn | - | -14.43 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.43 Mn |
| Mar 31, 2026 | -12.63 Mn |
| Dec 31, 2025 | -16.71 Mn |
| Sep 30, 2025 | -6.37 Mn |
| Jun 30, 2025 | -8.74 Mn |
| Mar 31, 2025 | -6.76 Mn |
| Dec 31, 2024 | -7.53 Mn |
| Sep 30, 2024 | -5.99 Mn |
| Jun 30, 2024 | -6.07 Mn |
| Mar 31, 2024 | -6.15 Mn |
| Jun 30, 2023 | -9.51 Mn |
| Mar 31, 2023 | -3.96 Mn |